Dec 21, 2018
Mylan expands access of ARV medicines to patients living with HIV/AIDS in South Africa
Mylan has concluded an agreement to acquire Ascendis Health’s manufacturing facility in Isando which further strengthens Mylan’s commitment to HIV patients in South Africa by establishing local presence in the country
South Africa has the largest HIV epidemic in the world and is home to 19% of people living with HIV/AIDS globally1
Johannesburg, South Africa, 21 December Taking another step towards its commitment on making high-quality medicines available to everyone who needs them, Global pharmaceutical company, Mylan, today announced the closure of the agreement for the acquisition of Ascendis Health’s manufacturing facility in Isando, Johannesburg. Through this facility, Mylan will further advance its commitment to enhance access to high-quality ARV medicines for the 7 million South Africans living with HIV2.
HIV is a public health priority for South Africa with 19% of the global population living with HIV in the country. The country also accounts for 15% of new infections and 11% of AIDS-related deaths, annually1.
Mylan President, Rajiv Malik commented, “Mylan’s global HIV initiative is one of the company’s key priorities and represents part of our continued commitment to reach patients in low- and middle-income countries with access to medicines across a broad array of therapeutic categories. Mylan’s innovations have helped fuel a steep decline in ARV drug costs over the last decade, and the integration of the Isando site into our global manufacturing network will help us to meet unmet patient needs in South Africa. Mylan has invested significantly in its scientific platform and created broad capacity for global ARV supply. With our scale, excellent formulation chemistry skills, process optimization and cutting-edge quality systems, Mylan is committed to continue setting new standards in healthcare the world over.”
Mr. Rakesh Bamzai, CEO and MD, for India and Emerging Markets at Mylan
stated, “Mylan has a strong and sustained commitment to expanding access to treatment for HIV/AIDS and other diseases around the world. For instance, 40% of patients globally who are being treated for HIV/AIDS with an antiretroviral depend on a Mylan product every day. The closure of the agreement for the acquisition of the Ascendis Health facility in Isando, is another milestone in our efforts to battle some of these devastating infectious diseases and is in line with our mission to provide the world's 7 billion people access to high-quality medicine. We look forward to working with the South African government to further expand access to quality medicines in the country."
Spread over an expanse of 2.34 Hectares, the facility at Isando will produce high quality antiretroviral medicines. The facility has the capacity to produce regular tablets, effervescent tablets semi solids and hard gelatin capsules
Mylan has committed significant investment to acquire this facility, which will create job opportunities for the local population in South Africa. The Company will further invest in the facility to create a state of the art manufacturing center for antiretrovirals. In addition, Mylan will also undertake initiatives like, upskilling the local team to global standards in critical areas of science, technology and manufacturing processes to produce high-quality ARV medicines.
Mylan is the number one provider of anti-retroviral medicines in the developing world with a focus on Africa. Mylan supplies ARV drugs to more than 100 countries around the world. In 2012, Mylan entered the South African market with a comprehensive portfolio of ARV medications, consisting of first- and second-line adult and pediatric therapies, including several dual and triple FDCs. Over the last few years, Mylan has been a significant contributor towards the treatment of the HIV epidemic in South Africa and the commitment towards acquiring this facility shows Mylan’s intent to build a sustainable and durable business in the country that positively impacts the lives of the population by enhancing access to critical, high quality affordable medicines
Mylan is among the largest suppliers of ARV medicines in South Africa both in private and state sector.
Mylan's Commitment to the HIV/AIDS Patient Community
Mylan is the world's largest supplier by volume of HIV/AIDS therapies. More than 40% of the 20 million patients on treatment worldwide depend on a Mylan product every day. For more than a decade, Mylan has been a leader in providing access to quality, dependable and affordable ARVs in 100 countries around the world. This includes introducing in 2009 the first generic one-tablet-once-a-day combination for developing countries – only three years after the originator product launched in the U.S. Since that time, Mylan has been the first to market with nearly half of the new products tentatively approved by the FDA under PEPFAR. Mylan was also the first generic drug maker to develop for low- and middle-income countries a heat-stable version of a drug critical for second-line regimens, and is the leading worldwide supplier of pediatric ARVs, including taste-masked and dispersible formulations. Mylan has long been a supporter of the patient community through the sponsorship of free community HIV/AIDS testing and clinical research. Watch this video to learn more about Mylan's commitment to people living with HIV/AIDS.